The potential of the MeyerZall therapeutic system was further unlocked with the development of the pro-emzaloid technology. This development opened the door to develop oral and other systemic medications and the ability to compete in any blockbuster market. Whilst one area of focus is to develop oral medications, MeyerZall continues to develop and improve on its range of exceptional topical preparations. The exponential growth in MeyerZall's technology that occurred during the development of oral and other medications have contributed to the company's immeasurable understanding of the value of Exorex and the company's other products. During 1999, MeyerZall raised capital from AMB Private Equity Partners Limited ("AMB"), a black empowerment private equity firm, in order to fund a research and development ("R&D") campaign that was used to add credibility to its products and enhance the understanding of its technology. The R&D efforts culminated in the discovery of a unique therapeutic system, referred to as Emzaloid™ technology, which was acting in the formulation of all MeyerZall products. Wide and far reaching findings emerging from research on the MeyerZall therapeutic system indicate that the Emzaloid™ has applicability in infectious disease treatment and has the potential to deliver agents to organelle and tissue types. Indeed, by virtue of the fact that the Emzaloid™ technology has the capacity to entrap most known active agents, its application in the industry is potentially limitless and includes such areas as tuberculosis ("TB"), malaria, anti-Aids therapy, gene delivery, as well as generic medications.